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http://dx.doi.org/10.1016/j.kjms.201Abstract A number of studies have shown that the transplantation of bone marrow-derived
mesenchymal stem cells (BMSCs) into the thinned infarct wall improves regional wall motion.
In this study, we hypothesized that the injection of biomaterials and MSCs into the infarcted
myocardium can preserve left ventricular (LV) function. To test this hypothesis, anterior acute
myocardial infarction (AMI) was induced in 34 rabbits and BMSCs with hydrogel composite were
prepared. One week after inducing AMI, 28 of the 34 rabbits were divided into four groups
(Groups AeD; three rabbits were used for bone marrow aspiration, and three rabbits died)
and all received an epicardial injection. Group A received BMSCs with hydrogel composite
marked by 5-bromodeoxyuridine (BrdU); Group B received BMSCs only marked by BrdU; Group
C received hydrogel only marked by BrdU; and Group D was the control group, which received
fetal bovine serum. Echocardiography was performed before AMI was induced, 1 week after
AMI, and 4 weeks after the epicardial injection. The results were compared with those before
AMI, and the rabbits of all the four groups had significantly larger LV end-diastolic diameter
(LVDd), thinner anterior wall (AW), lower LV ejection fraction (LVEF), lower VS and VE
(p< 0.05) 1 week after AMI, which were more significant in Group A (p< 0.05). Compared with
1 week after AMI, Group A and Group B had significantly smaller LVDd, thicker AW, larger LVEF,
larger VS and VE (p< 0.05) 4 weeks after the epicardial injection, which were more significantng authors declare no conflicts of interest.
of Echocardiography, Renmin Hospital, Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan
ail.com (J. Chen).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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174 J. Chen et al.in Group A (p< 0.05); however, there was no significant difference in Group C and Group D.
These results suggested that BMSCs with hydrogel composite could serve as an injectable
biomaterial that prevents LV remodeling and dilation, and improves local systolic and diastolic
function after AMI.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Left ventricle (LV) remodeling and subsequent heart fail-
ure after myocardial infarction (MI) are often progressive.
This process results in a sequence of molecular, cellular,
and physiological responses that lead to LV dilation, which
may eventually lead to decompensation with congestive
heart failure [1]. Paradoxical systolic bulging caused by
infarct expansion and thinning can impair LV systolic
function [2].
Recently, transplantation of bone marrow-derived
mesenchymal stem cells (BMSCs) into the thinned infarct
wall to replace the necrotic cardiomyocytes has been
shown to improve regional wall motion, particularly the
reduction in the degree of dyskinesis of the infarct zone
[3e5]. Experimental evidence shows that MSCs are a
promising cell type for mediating cell therapy for MI. These
cells retain the capacity to produce cells of all three germ
layers and, under specific culture conditions; MSCs can
differentiate into synchronously beating cardiomyocytes
[6]. Although the transdifferentiation ability of BMSCs into
cardiomyocytes has been questioned [7], MSCs still hold
promise in cell-based therapy for MI because they can
secrete a variety of cytokines and growth factors that
stimulate angiogenesis, prevent myocardial death in
ischemic conditions, and attract stem cell homing [8e10].
Although the underlying mechanisms are a matter of
debate, engraftment of MSCs into ischemic myocardial
tissue and their consecutive paracrine effects are intended
to substantially attenuate morphological and functional
postinfarction remodeling [9].
However, the fraction of transplanted cells retained
and engrafted within the myocardium has been found to
be below 3% shortly after transplantation [11,12]. Poly-
meric hydrogels are crosslinked polymer networks, which
can take up a large quantity of water, and render them
biocompatible, similar to soft tissues [13]. Intelligent
hydrogels that are capable of changing their shape,
structure, or volume of exposure to external stimuli such
as pH [14,15], temperature [16,17], antigen [18], electric
field [19], and photofield [20] have also been developed.
These hydrogels are advantageous in clinical applications
due to their fluidity, which enables the materials to be
introduced into the site-specific organ, tissue, or body
cavity with improved patient applicability and comfort
[17].
The objective of this study was to demonstrate the
feasibility and tolerability of injecting BMSCs with a novel
synthetic hydrogel into an infarcted wall of a rabbit and
also to investigate whether hydrogel implantation improves
an infracted LV function.Materials and methods
The experiments were performed in 34 male rabbits: three
rabbits, of 1.5-kg body weight, were used for the harvest of
BMSCs; the other 31 rabbits, with an initial body weight of
2.2e2.6 kg, were used for the MI model. All experimental
procedures were performed in accordance with the Guide
for the Care and Use of Laboratory Animals published by the
U.S National Institutes of Health, and the study protocol
was approved by the Institutional Animal Care Committee
of Wuhan University, People’s Republic of China.
Preparation of BMSCs
Bone marrow was aspirated from the tibia of 2-month-old
rabbits with an 18-gauge needle connected to a syringe
containing heparin. Bone marrow cells were flushed and
cultured with Dulbecco’s modified Eagle’s medium (DMEM)/
F12 medium (Gibco) supplemented with 20% fetal bovine
serum (FBS; Gibco) and penicillin (100 U/mL)/streptomycin
(100 U/mL) at 37 C in humid air with 5% CO2. Two days
after sowing, the BMSCs had adhered to the bottom of
culture plates and the hematopoietic cells remained sus-
pended in the medium. The nonadherent cells were
removed by changing the medium at 48 hours and every 3
days thereafter. BMSCs were labeled with 25 mg/mL 5-
bromodeoxyuridine (BrdU) 10 mL for 24 hours.
Cell encapsulation of the hydrogel
The poly(ethylene glycol)-b-polycaprolactone-(dodecane-
dioic acid)-polycaprolactone-poly(ethylene glycol) (MPEGe
PCLeMPEG) solution (10 wt.%) and a-cyclodextrin (a-CD)
solution (10 wt.%) were sterilized in an autoclave before
use.
BMSCs were seeded onto 96-well plates at a density of
1 104 cells/well. After 12 hours of incubation for adhe-
sion, the culture medium was replaced by 200 mL of DMEM/
F12 containing particular concentrations of the a-CD/
MPEGePCLeMPEG hydrogel co-polymer, followed by incu-
bation at 37 C in humidified 5% CO2 atmosphere for 48
hours. The medium with polymer was then replaced with
fresh medium containing 20 mL of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
solution (5 mg/mL) and incubated for 4 hours. The super-
natant was aspirated and the formazan crystals were set
aside in 200 mL of dimethyl sulfoxide. Aliquots were drawn
from each well and the optical density (OD) was spectro-
photometrically measured in a Microplate Reader Model 550
(Bio-Rad, USA) at 490 nm. Untreated cells were chosen as
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Protective effects of BMSCs on cardiac function 175the control with 100% viability, and cells without the
addition of MTT were used as a blank to calibrate the
spectrophotometer to zero absorbance. The relative cell
viability (%) was calculated using the formula ODtreated/
ODcontrol by comparing the control cells.
BMSCs were removed from the culture flasks with trypsin
and centrifuged to make a pellet (5 106 cells/shot). The
cell pellet was resuspended in a-CD solution with gentle
mixing using a micropipettor. The cell/a-CD solution mix-
tures were then aspirated and mixed with MPEGePCLeM-
PEG solution to form a solid hydrogel in a six-well plate.
Fresh medium was then added to the plates. After incu-
bation for 3 days, the medium in the well was pipetted out.
The hydrogel with cells is washed three times with
phosphate-buffered saline, fixed in 2.5% glutaraldehyde for
2 hours, dehydrated with a graded ethanol series, frozen
under liquid nitrogen, and freeze dried. After gold coating,
the morphology of cells in the hydrogel was examined by
scanning electron microscopy.
Animal model of MI
Rabbits were anesthetized with an intravenous injection of
3% pentobarbital sodium (30 mg/kg). The rabbits’ heart was
exposed by performing a 3e5-cm left lateral thoracotomy,
and the left anterior descending coronary artery was
ligated by a 5-0 silk suture, and the chest was closed. The
operation was performed with electrocardiogram moni-
toring, and rabbits with obvious ST segment elevation in
lead V1eV6 were considered as successful MI models.
Penicillin G benzathine (800,000 U/day) was intramuscu-
larly administered for 3 days after the operation.
Implantation surgery
Seven days after inducing MI, the rabbits were randomized
into the following four groups: the BMSCsþ hydrogel group
(Group A, n Z 7); the BMSCs group (Group B, n Z 7); the
hydrogel group (Group C, n Z 7); and the control group
(Group D, n Z 7).
After anesthetization, the hearts were exposed through
a second thoracotomy, and 200 mL solutions were injected
into four sites in the infarcted myocardium (each
injection Z 50 mL). In Group A, 2 107 BMSCs were sus-
pended in 100 mL of a-CD solution (10 wt.%, dissolved in
culture medium), delivered with 100 mL of MPEGePCLeM-
PEG solution through a Duploject applicator, which con-
tained the two parts in separate syringes and provided
simultaneous mixing during delivery. In Group B, 200 mL of
2 107 BMSCs were injected into the myocardium. In Group
C, 200 mL of DMEM/F12 medium without BMSCs were
injected into the myocardium. In Group D, 200 mL FBS were
injected into the myocardium.
Conventional echocardiography and quantitative
tissue velocity imaging
The LV dimension and function were measured by echo-
cardiography (GE Vivid 7, USA; M10S transducer,
4e12 MHz). The echocardiography examination was per-
formed before MI, 7 days after MI, and 28 days after the
176 J. Chen et al.implantation surgery by two researchers blinded to the
treatment allocation. The LV end-diastolic diameter
(LVDd), anterior wall thickness (AWT) in end diastole, and
LV ejection fraction (LVEF) were measured from at least
three consecutive cardiac cycles.
Tissue velocity imaging (TVI) at two-chamber apical view
was stored for offline analysis. Using quantitative TVI
(QTVI), the sampling point was located on the endocardial
myocardium of AW at the middle and basal levels. From the
QTVI curve, velocity in systole (VS) and velocity in early
diastole (VE) were measured in at least three consecutive
cardiac cycles.
Histology and immunohistochemistry
Four weeks after the treatment, the rabbit LVs were
retrieved and freshly frozen in Tissue-Tek O.C.T. freezing
medium, and then sectioned at five different transversal
levels around the injection site. Fluorescence microscopy
was used to detect BrdU-labeled transplanted BMSCs
around the injection sites. The sections were then stained
with Masson’s trichrome methods. In each section, the
infarcted and noninfarcted areas were measured by auto-
mated computer image analysis. The infarct size (%) was
calculated from the ratio of surface area of infarct wall and
the entire surface area of the LV.
For immunohistochemical analysis, 4-mm-thick sections
were stained using antibodies against a-smooth muscle
actin (a-SMA, 1:100 dilutions; Boster, China) to label
mature blood vessels. The sections were incubated with the
primary antibody diluted in staining buffer, and then incu-
bated again with a horseradish peroxidase-conjugated
goateanti-mouse secondary antibody (Boster; China) to
visualize labeled vessels. Hematoxylin was used for coun-
terstaining. Blood vessel density was expressed as the
number of vessels at 200 high-power magnification fields.
Statistical analysis
All results were presented as the mean  standard devia-
tion. The data were compared and intergroup differences
were analyzed by one-way analysis of variance with the
post hoc Bonferroni test, and variance ratio (F ) wasTable 2 Comparison of QTVI parameters in four rabbit groups b
surgery.
Group Before AMI 1 we
VS (cm/s) VE (cm/s) VS (cm/s)
Group A (n Z 7) 7.41  1.35 8.32  1.50 4.54  1.4
Group B (n Z 7) 7.63  1.41 8.19  1.77 4.61  1.3
Group C (n Z 7) 7.59  1.43 8.46  1.68 4.46  1.4
Group D (n Z 7) 7.54  1.38 8.43  1.65 4.52  1.5
*p< 0.05 versus before AMI.
**p< 0.05 versus 1 week after AMI.
***p< 0.05 versus Group B.
Group A: group of BMSCs＋hydrogel; group B: group of BMSCs; group
AMIZ acute myocardial infarction; BMSCZ bone marrow-derived me
VE Z peak velocity in diastole; VS Z peak velocity in systole.calculated. Statistical analyses were performed using SPSS
version 13.0 software (SPSS Inc., Chicago, IL, USA). A
p value< 0.05 was taken to be significant.Results
A total of 34 rabbits were initially included in this study.
Three rabbits were used for bone marrow aspiration, and
three rabbits died during or immediately after the infarct
surgery because of ventricular fibrillation. After the sur-
gery, there was 100% survival in all groups. The LV function
and volume measurements and histological analysis were
performed on these 28 rabbits.
Effects of hydrogel implantation on conventional
echocardiography parameters after MI
As shown in Table 1, compared with results before MI, there
was a decrease in LV dilation, AWT thinning, and LVEF in all
rabbits 7 days after MI. Twenty-eight days after the im-
plantation surgery, BMSCsþ hydrogel or BMSCs injection
inhibited LV dilation, AWT thinning, and LVEF decrease
following MI: in the BMSCsþ hydrogel group, LVDd, AWT,
and LVEF were 12.03  1.25 mm, 1.80  0.28 mm, and
69.61%  6.92%, respectively. In the BMSCs group, LVDd,
AWT, and LVEF were 12.81  1.24 mm, 1.71  0.30 mm, and
65.16%  7.42%, respectively. However, the BMSCsþ hy-
drogel group had a trend for smaller LVDd, thicker AWT, and
significantly greater LVEF compared with the BMSCs group.
There was no significant improvement in the hydrogel and
control groups 28 days after the implantation surgery
(Table 1).
Effects of hydrogel implantation on QTVI
parameters after MI
Compared with results before MI, rabbits of all four groups
had significantly lower VS and VE (p< 0.05) 7 days after MI.
Compared with 7 days after MI, the BMSCsþ hydrogel group
or BMSCs group had significantly larger VS and VE (p< 0.05)
28 days after the implantation surgery, which were more
significant in Group A (p< 0.05); but there were noefore AMI, 1 week after AMI and 4 weeks after implantation
ek after AMI 4 weeks after implantation surgery
VE (cm/s) VS (cm/s) VE (cm/s)
3* 5.51  1.53* 6.11  1.45**,*** 6.41  1.64**,***
5* 5.42  1.64* 5.76  1.63** 5.95  1.57**
7* 5.39  1.46* 4.65  1.54 5.50  1.61
4* 5.48  1.62* 4.54  1.53 5.63  1.49
C: group of hydrogel; group D: group of controls.
senchymal stem cell; QTVIZ quantitative tissue velocity imaging;
Figure 1. Quantitative tissue velocity imaging curve of Group A 4 weeks after implantation surgery.
Protective effects of BMSCs on cardiac function 177significant changes in the hydrogel and control groups
(Table 2, Figs. 1e4).
Histology and immunohistochemistry
Four weeks after the surgery, examination by fluorescence
microscopy showed that BMSCs labeled with BrdU before
implantation were detected around the injection sites in
both groups of BMSCs implanted with and without hydrogel,
which suggested that the implanted cells retained andFigure 2. Quantitative tissue velocity imaging curve of Group B
those of Group A. VE Z peak velocity in diastole; VS Z peak velocsurvived in the infarction sites. Statistical analysis showed a
significant increase in the BrdU-labeled cells in Group A
(BMSCsþ hydrogel, 2147  241 mm2) when compared with
Group B (BMSCs, 851  149 mm2); Groups C and D had no
BMSCs labeled with BrdU around the injection sites.
The infarct sizes in Groups A, B, C, and D were
19.45%  2.36%, 24.12%  1.97%, 29.52%  2.24%, and
30.01%  2.13%, respectively. Statistical analysis showed a
significant reduction in the infarct size after cell implan-
tation (Groups A and B vs. Groups C and D, p< 0.05). The4 weeks after implantation surgery, VS and VE are lower than
ity in systole.
Figure 3. Quantitative tissue velocity imaging curve of Group C 4 weeks after implantation surgery, VS and VE are lower than
those of Groups A and B. VE Z peak velocity in diastole; VS Z peak velocity in systole.
178 J. Chen et al.injection of BMSCs with hydrogel further reduced the
infarct size when compared with implantation of BMSCs
alone (vessels at the border of infarct area were labeled
with anti-a-SMA, which is expressed in smooth muscle cells
in mature blood vessels) [21]. A larger number of micro-
vessels at the border of the infarct area were positively
stained in the BMSCs group implanted with hydrogel than in
the other three groups. In addition, the number of micro-
vessels in the cell group was significantly larger than the
control (p< 0.05; Figs. 5 and 6).Figure 4. Quantitative tissue velocity imaging curve of Group D
those of Groups A and B. VE Z peak velocity in diastole; VS Z peaDiscussion
Myocardial cell therapy with BMSCs is an emerging thera-
peutic option after MI [5]. BMSCs can be transplanted
autologously without the need for immunosuppression and
expanded in vitro. Although the underlying mechanisms are
a matter of debate, engraftment of BMSCs into ischemic
myocardial tissue and their consecutive paracrine effects
are intended to substantially attenuate morphological and
functional postinfarction remodeling [9]. However, the4 weeks after implantation surgery, VS and VE are lower than
k velocity in systole.
Figure 5. Myocardium in the infarction area of Group A 4
weeks after implantation surgery. Hematoxylin and eosin
staining, 200; there are lots of myocardial cells, transverse
striations, and blood capillaries.
Protective effects of BMSCs on cardiac function 179fraction of transplanted cells retained and engrafted within
the myocardium has been found to be below 3% shortly
after transplantation [11,12]. Improving the efficacy of a
sustained myocardial cell delivery might result in improved
functional outcome. Therefore, the improvement of
transplantation efficacy might positively influence their
therapeutic potential.
Our results indicate that BMSCs transplant retention and
survival in infarcted myocardium were enhanced by injec-
tion of BMSCs with a-CD/MPEGePCLeMPEG hydrogel, which
can improve the LV remodeling and function more signifi-
cantly than transplant of BMSCs alone. The study by Mathieu
and co-workers showed that the cardiac function varied over
the 8 weeks, especially in the hydrogel group, which showed
improved cardiac function at 4 weeks but were even worseFigure 6. Myocardium in the infarction area of Group A 4
weeks after implantation surgery, immunofluorescence stain-
ing, confocal microscopy, 1000; there are lots of 5-
bromodeoxyuridine-labeled bone marrow-derived mesen-
chymal stem cells and myocardial transverse striations.at 8 weeks after therapy [22]. Our results show that all the
cardiac morphology and function improved significantly in
groups with BMSCs therapy, while there was no change in
groups with hydrogel or controls. Maybe these differences
are due to different animal models and follow-up time. In
the first weeks of MI, the activation of matrix metal-
loproteases damaged the cardiac extracellular matrix
(ECM), whichmight inhibit the adhesion of transplanted cells
[23,24]. The rapid gelation kinetics of the hydrogel allowed
effective entrapment of BMSCs at the site of injection [25].
Furthermore, the polymer chains of the hydrogel were
highly hydrated, making the hydrogel similar to natural tis-
sues and suitable for cell growth [26]. In the in vitro study,
no significant cytotoxicity was found in the hydrogel, and the
morphology of the BMSCs in the hydrogel was spindle-like,
which indicated that they were in a viable state.
A number of studies have demonstrated that BMSCs
contain endothelial precursors, and the implantation of
BMSCs could induce neovascularization in ischemic
myocardium [27,28]. The a-CD/MPEGePCLeMPEG hydrogel
did not induce angiogenesis, but we demonstrated that
implantation of BMSCs using the hydrogel increased vessel
density around the border of the infarct compared with
BMSCs implanted alone as confirmed in our previous study
[29]. This favorable result could be explained as the
consequence of increased cell retention and survival
induced by the hydrogel. By increasing the vessel density,
the therapeutic effect was subsequently raised. Therefore,
we could demonstrate that injection of BMSCs with a-CD/
MPEGePCLeMPEG hydrogel could enhance the beneficial
effects of BMSC implantation on cardiac function,
contractility, and remodeling. The underlying mechanism is
likely to increase cell retention and survival when cells
were implanted with hydrogel, which induces more neo-
vascular formation in the infarcted myocardium.
Our results show that the combination of the two thera-
pies may have some synergistic benefits that cannot be
achieved from either of them alone: hydrogel can enhance
cell retention and serve as an ECM in which the transplanted
cells can grow. Although this study shows that intra-
myocardial injection of BMSCs with a-CD/MPEGePCLeMPEG
hydrogel after MI could increase cell retention and vessel
density at the border of the infarct area, improve LV func-
tion, and prevent LV remodeling, the long-term effects of
this therapy and the secretion and differentiation of
implanted BMSCs in hydrogel still need further investigation.Conclusion
This study shows that intramyocardial injection of BMSCs
with a-CD/MPEGePCLeMPEG hydrogel into infarcted
myocardium in rabbits could improve the impaired cardiac
function compared with implantation of BMSCs only. Our
study may have implications for further experimental and
clinical studies.Acknowledgments
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